natgillin/translations-raw huggingface dataset:
1 Mean toxin neutralising titre obtained after repeated vaccination of a half dose in rabbits.
1 Srednji toksin neutralizirajući titar dobiven nakon ponovnog cijepljenja s pola doze u kunića
1 Mean toxin neutralising titre obtained after repeated vaccination of a half dose in rabbits.
1 Srednji toksin neutralizirajući titar dobiven nakon ponovnog cijepljenja s pola doze u kunića.
1 Measured at first session, if there was more than one surgery session.
1 Mjereno na prvoj obradi ako je bilo više od jedne kirurške obrade.
1 measuring syringe.
1 mjerna štrcaljka
1 Median is the Kaplan-Meier estimate of the median survival time
1 Medijan je Kaplan-Meierova procjena medijana vremena preživljenja
1 metering pump of 30 grams
1 odmjerna pumpica s 30 grama
1 mg capsule shell contains gelatin, titanium dioxide (E171), indigotine (E132) and yellow iron oxide (E172) and white and black ink.
Ovojnica kapsule od 1 mg sadrži: želatinu, titanijev dioksid (E171), indigotin (E132) i željezov oksid, žuti (E172) i bijelu i crnu tintu.
1 mg capsule shell contains: white ink - shellac, titanium dioxide (E171), simethicone, propylene glycol (E1520) and ammonium hydroxide (E527); black ink - shellac, iron oxide black (E172), propylene glycol (E1520) and ammonium hydroxide (E527).
Ovojnica kapsule od 1 mg sadrži: bijelu tintu - šelak, titanijev dioksid (E171), simetikon, propilenglikol (E1520) i amonijev hidroksid (E527); crna tinta - šelak, željezov oksid crni (E172), propilenglikol (E1520) i amonijev hidroksid (E527).
1 mg film-coated tablets of 5mm x 10mm: Light blue, capsular-shaped, biconvex tablets debossed with “Pfizer” on one side and “CHX 1.0” on the other side.
1 mg filmom obložene tablete dimenzija 5 mm x 10 mm: Svjetloplave, bikonveksne tablete u obliku kapsule, s oznakom "Pfizer" na jednoj i "CHX 1.0" na drugoj strani.
1 mg once daily
1 mg jedanput dnevno
1 mg once daily
Noretindron
1 mg tablet: pale yellow, round, biconvex tablets of 6 mm, marked with the Bayer cross on one side and 1 and an “R” on the other side.
1 mg tableta: blijedožute, okrugle, bikonveksne tablete od 6 mm, označene Bayerovim križem s jedne strane te brojem 1 i slovom “R” s druge strane.
1 mg trabectedin
1 mg trabektedina
1 mg twice daily
1 mg dvaput na dan
1 mg vials:
1 mg bočice:
1 mg/ethinyl estradiol
1 mg/etinilestradiola 0,035 mg
1 mg/kg body weight subcutaneously once daily
1 mg/kg tjelesne težine supkutano jedanput na dan
1 mg/kg body weight subcutaneously twice daily
1 mg/kg tjelesne težine supkutano dva puta na dan
1 mg/kg bw subcutaneously once daily
1 mg/kg TT supkutano jedanput na dan
1 mg/kg bw subcutaneously twice daily
1 mg/kg TT supkutano dva puta na dan
1 mg/kg bw subcutaneously).
1 mg/kg TT).
1 mg/kg subcutaneously once daily without initial bolus.
1 mg/kg supkutano jedanput na dan bez inicijalnog bolusa.
1 mg/kg twice daily (every 12 hours) adult dosing
0,5 mg/kg dva puta dnevno (svakih 12 sati)
1 mg/kg twice daily (every 12 hours) adult dosing
1 mg/kg dva puta dnevno (svakih 12 sati) doziranje kao u odraslih
1 mg/kg/day
1 mg/kg na dan
1 mg/m2 to 0.7 mg/m2)
1 mg/m2 na 0,7 mg/m2)
1 mg/ml butylhydroxytoluene (E321: as antioxidant)
1 mg/ml butilhidroksitoluen (E321: kao antioksidans)
1 mg/ml butylhydroxytoluene (E321: as antioxidant).
1 mg/ml butilhidroksitoluen (E321: kao antioksidans)
1 mixing bottle + 1 oral syringe + 1 screw cap with syringe-port capability
1 štrcaljka za usta+ 1 zatvarač s navojem u koji se može umetnuti štrcaljka
1 mixing cup with joined lid
1 čašu za miješanje s pričvršćenim poklopcem
1 ml (1 dose)
1 ml( 1 doza)
1 ml (20 mg) twice daily
1 ml (20 mg) dvaput na dan
1 ml ampoule white - yellow ring
ampula od 1 ml bijeli - žuti prsten
1 ml ampoule white-yellow ring
ampula od 1 ml bijeli-žuti prsten
1 ml ampoule yellow - red ring
ampula od 1 ml žuti - crveni prsten
1 ml ampoule yellow-red ring
ampula od 1 ml žuti-crveni prsten
1 ml ampoules for use with Breelib or I-Neb nebulisers:
ampule od 1 ml za primjenu pomoću atomizatora Breelib ili I-Neb:
1 ml ampoules, colourless, glass type I, containing 1 ml nebuliser solution, ring coded with two coloured rings (yellow - red).
ampule od 1 ml, od bezbojnog stakla tipa I, s 1 ml otopine za atomizator, označene s dva prstena u različitim bojama (žuti - crveni).
1 ml and 10 ml glass vials: 4 years.
1 ml i 10 ml staklene bočice: 4 godine.
1 ml contains 1.12 mg of cabergoline.
1 ml sadržava 1,12 mg kabergolina.
1 ml contains 100 IU (3.5 mg) insulin human.
1 ml sadrži 100 IU (3,5 mg) humanog inzulina
1 ml contains 100 IU (3.5 mg) insulin human.
1 ml sadrži 100 IU (3,5 mg) humanog inzulina.
1 ml contains 100 U of laronidase.
1 ml sadrži 100 U laronidaze.
1 ml contains 100 units (3.64 mg) insulin glargine
1 ml sadrži 100 jedinica (3,64 mg) inzulina glargina
1 ml contains 100 units (3.64 mg) insulin glargine
1 ml sadrži 100 jedinica (3,64 mg) inzulina glargina.
1 ml contains 150 mg lidocaine and 50 mg prilocaine.
1 ml sadržava 150 mg lidokaina i 50 mg prilokaina.
1 ml contains 250 microgram (8.0 million IU) interferon beta-1b per ml when reconstituted.
1 ml sadrži 250 mikrograma (8,0 milijuna IU) interferona beta-1b nakon pripreme otopine.
1 ml contains 250 microgram (8.0 million IU) interferon beta-1b when reconstituted.
1 ml sadrži 250 mikrograma (8,0 milijona IU) interferona beta-1b nakon pripreme otopine za primjenu.
1 ml contains 250 microgram (8.0 million IU) interferon beta-1b when reconstituted.
1 ml sadrži 250 mikrograma (8,0 milijuna IU) interferona beta-1b nakon pripreme otopine.
1 ml contains 30 mg of iron.
1 ml sadrži 30 mg željeza.
1 ml contains 4 mg of nitisinone.
1 ml sadrži 4 mg nitizinona.
1 ml contains 40 IU (1.4 mg) insulin human.
1 ml sadrži 40 IU (1,4 mg) humanog inzulina
1 ml contains 40 IU (1.4 mg) insulin human.
1 ml sadrži 40 IU (1,4 mg) humanog inzulina.
1 ml contains 750 U of pegaspargase.
1 ml sadrži 750 U pegaspargaze.
1 ml contains:
1 ml sadržava:
1 ml contains:
1 ml sadrži
1 ml contains: Perflutren-containing microspheres 5 - 8 x 108, with a mean diameter range of 2.5 - 4.5 µm, equivalent to 0.19 mg perflutren gas per ml.
1 ml sadrži: 5 - 8 x 108 mikrosfera s perflutrenom, srednjeg raspona promjera 2,5 - 4,5 µm, što odgovara 0,19 mg perflutren plina po ml.
1 ml injection syringe
Štrcaljka za injekciju od 1 ml
1 ml Luer-lock tip syringe x1
štrcaljku od 1 ml s priključkom tipa Luer-lock x1
1 ml of 1 mg/ml topotecan solution
1 ml otopine topotekana od 1 mg/ml
1 mL of concentrate contains 3.5 mg of dinutuximab.
1 ml koncentrata sadrži 3,5 mg dinutuksimaba.
1 ml of concentrate for solution for infusion contains 1 mg of agalsidase alfa*.
1 ml koncentrata za otopinu za infuziju sadrži 1 mg agalzidaze alfa*.
1 ml of concentrate for solution for infusion contains 1 mg topotecan (as hydrochloride).
1 ml koncentrata za otopinu za infuziju sadržava 1 mg topotekana (u obliku topotekanklorida).
1 mL of emulsion contains 1 mg of ciclosporin.
1 ml emulzije sadrži 1 mg ciklosporina.
1 ml of KIOVIG contains 100 mg of human protein of which at least 98% is immunoglobulin G (IgG).
1 ml lijeka KIOVIG sadrži 100 mg ljudskog proteina od kojeg je imunoglobulina G (IgG) najmanje 98%.
1 ml of KRYSTEXXA should be withdrawn from the vial into a sterile syringe.
1 ml lijeka KRYSTEXXA treba navući iz bočice u sterilnu štrcaljku.
1 ml of Norvir solution (for pharmacokinetic enhancer purposes) contains 344.0 mg of alcohol and 265.7 mg propylene glycol.
1 ml Norvir otopine (sa svrhom farmakokinetičkog pojačivača) sadrži 344,0 mg alkohola 265,7 mg propilenglikola.
1 ml of reconstituted solutions contains 90 mg enfuvirtide.
1 ml pripremljene otopine sadrži 90 mg enfuvirtida.
1 ml of solution contains 10 mg maropitant (as maropitant citrate monohydrate).
1 ml otopine sadržava10 mg maropitanta u obliku maropitant citrat monohidrata.
1 ml of solution contains 30 mg of iron as ferumoxytol.
1 ml otopine sadrži 30 mg željeza u obliku ferumoksitola.
1 mL of solution contains 40 micrograms of travoprost
1 ml otopine sadrži 40 mikrograma travoprosta
1 ml of solution contains 6 mg of liraglutide*.
Jedan ml otopine sadrži 6 mg liraglutida*.
1 mL of solution for injection contains 300 MBq of florbetaben (18F) at the date and time of calibration.
1 ml otopine za injekciju sadrži 300 MBq florbetabena (18F) na dan i sat kalibriranja.
1 ml of solvent in an oral applicator (type I glass) with a plunger stopper and a protective tip cap (rubber butyl).
1 ml otapala u oralnom aplikatoru (staklo tipa I) sa čepom klipa i zaštitnim zatvaračem vrha (butil guma).
1 ml of sterile solution contains 1.850 GBq Yttrium (90Y) chloride, at the date of calibration, corresponding to 92 ng of Yttrium.
1 ml sterilne otopine sadrži 1,850 GBq itrijevog (90Y) klorida, na datum kalibracije, što odgovara 92 ng itrija.
1 ml of suspension contains 10 mg brinzolamide and 2 mg brimonidine tartrate
1 ml suspenzije sadrži 10 mg brinzolamida i 2 mg brimonidin tartarata
1 ml of suspension contains 10 mg brinzolamide and 5 mg timolol (as timolol maleate)
1 ml suspenzije sadrži 10 mg brinzolamida i 5 mg timolola (u obliku timololmaleata).
1 mL of suspension contains 10 mg of brinzolamide and 2 mg of brimonidine tartrate equivalent to 1.3 mg of brimonidine.
Jedan ml suspenzije sadrži 10 mg brinzolamida i 2 mg brimonidin tartarata, što odgovara 1,3 mg brimonidina.
1 ml of suspension in a prefilled syringe (type I glass) with a plunger stopper (rubber butyl).
1 ml suspenzije u napunjenoj štrcaljki (staklo tip I) sa čepom klipa ( butil guma).
1 ml of suspension in a prefilled syringe (type I glass) with a plunger stopper (rubber butyl).
1 ml suspenzije u napunjenoj štrcaljki (staklo tipa I) sa čepom klipa od butil gume.
1 ml of suspension in a vial (type I glass) for 2 doses with a stopper (rubber butyl).
1 ml suspenzije u bočici (staklo tip I) za 2 doze sa čepom (butilna guma).
1 ml of suspension in a vial (type I glass) with a plunger stopper (rubber butyl).
1 ml suspenzije u bočici (staklo tip I) sa čepom klipa (butil guma).
1 ml of suspension in pre-filled syringe (glass) without needle with a plunger stopper (gray chlorobutyl ).
1 ml suspenzije u napunjenoj štrcaljki (staklo) bez igle s čepom klipa (siva klorbutilna guma).
1 ml of Synagis solution contains 100 mg of palivizumab*.
ml Synagis otopine sadrži 100 mg palivizumaba*.
1 ml of the reconstituted dispersion contains 8 microlitres sulphur hexafluoride microbubbles.
1 ml rekonstituirane disperzije sadrži 8 mikrolitara mikromjehurića sumporovog heksafluorida.
1 ml of the solution contains 100 units insulin detemir* (equivalent to 14.2 mg).
1 ml otopine sadrži 100 jedinica detemir inzulina* (što odgovara 14,2 mg).
1 ml powder
1 ml praha+ 1 ml otapala
1 ml pre-filled syringe containing 60 mg of denosumab (60 mg/ml).
Napunjena štrcaljka od 1 ml sadrži 60 mg denosumaba (60 mg/ml).
1 ml solution contains 100 international units insulin human (equivalent to 3.5 mg),
1 ml otopine sadrži 100 internacionalnih jedinica humanog inzulina (što odgovara 3,5 mg),
1 ml solution contains 100 units insulin aspart (equivalent to 3.5 mg).
1 ml otopine sadrži 100 jedinica aspart inzulina (što odgovara 3,5 mg).
1 ml solution contains 100 units insulin aspart* (equivalent to 3.5 mg).
1 ml otopine sadrži 100 jedinica aspart inzulina* (što odgovara 3,5 mg).
1 mL solution contains 100 units of insulin degludec (equivalent to 3.66 mg)
1 ml otopine sadrži 100 jedinica degludek inzulina (što odgovara 3,66 mg),
1 mL solution contains 100 units of insulin degludec/insulin aspart (equivalent to 2.56 mg/1.05 mg)
1 ml otopine sadrži 100 jedinica degludek inzulina/aspart inzulina (što odgovara 2,56 mg/1,05 mg),
1 mL solution contains 200 units of insulin degludec (equivalent to 7.32 mg)
1 ml otopine sadrži 200 jedinica degludek inzulina (što odgovara 7,32 mg),
1 ml solution contains 40 international units insulin human (equivalent to 1.4 mg),
1 ml otopine sadrži 40 internacionalnih jedinica humanog inzulina (što odgovara 1,4 mg),
1 ml solution for infusion contains 30 mg of iron as ferumoxytol.
1 ml otopine za infuziju sadrži 30 mg željeza u obliku ferumoksitola.
1 ml solution for injection (100 µg/ml darbepoetin alfa) in a type 1 glass vial with fluoropolymer laminated elastomeric stopper and an aluminum seal with flip-off dust cover.
1 ml otopine za injekciju (100 µg/ml darbepoetina alfa) u bočici od stakla tipa 1 s elastomernim čepom laminiranim fluoropolimerom i aluminijskim prstenom s „flip-flop“ poklopcem.
1 ml solution for injection (200 µg/ml darbepoetin alfa) in a type 1 glass vial with fluoropolymer laminated elastomeric stopper and an aluminum seal with flip-off dust cover.
1 ml otopine za injekciju (200 µg/ml darbepoetina alfa) u bočici od stakla tipa 1 s elastomernim čepom laminiranim fluoropolimerom i aluminijskim prstenom s „flip-flop“ poklopcem.
1 ml solution for injection (25 µg/ml darbepoetin alfa) in a type 1 glass vial with fluoropolymer laminated elastomeric stopper and an aluminum seal with flip-off dust cover.
1 ml otopine za injekciju (25 µg/ml darbepoetina alfa) u bočici od stakla tipa 1 s elastomernim čepom laminiranim fluoropolimerom i aluminijskim prstenom s „flip-flop“ poklopcem.
1 ml solution for injection (300 µg/ml darbepoetin alfa) in a type 1 glass vial with fluoropolymer laminated elastomeric stopper and an aluminum seal with flip-off dust cover.
1 ml otopine za injekciju (300 µg/ml darbepoetina alfa) u bočici od stakla tipa 1 s elastomernim čepom laminiranim fluoropolimerom i aluminijskim prstenom s „flip-flop“ poklopcem.
1 ml solution for injection (40 µg/ml darbepoetin alfa) in a type 1 glass vial with fluoropolymer laminated elastomeric stopper and an aluminum seal with flip-off dust cover.
1 ml otopine za injekciju (40 µg/ml darbepoetina alfa) u bočici od stakla tipa 1 s elastomernim čepom laminiranim fluoropolimerom i aluminijskim prstenom s „flip-flop“ poklopcem.
1 ml solution for injection (500 µg/ml darbepoetin alfa) in a pre-filled pen with type 1 glass syringe and stainless steel 27 gauge needle.
1 ml otopine za injekciju (500 µg/ml darbepoetina alfa) u napunjenoj brizgalici sa štrcaljkom od stakla tipa 1 i iglom od 27 gauge od nehrđajućeg čelika.
1 ml solution for injection (500 µg/ml darbepoetin alfa) in a type 1 glass pre-filled syringe with stainless steel 27 gauge needle.
1 ml otopine za injekciju (500 μg/ml darbepoetina alfa) u napunjenojštrcaljki od stakla tipa 1 s iglom od 27 gauge od nehrđajućeg čelika.
1 ml solution for injection (60 µg/ml darbepoetin alfa) in a type 1 glass vial with fluoropolymer laminated elastomeric stopper and an aluminum seal with flip-off dust cover.
1 ml otopine za injekciju (60 µg/ml darbepoetina alfa) u bočici od stakla tipa 1 s elastomernim čepom laminiranim fluoropolimerom i aluminijskim prstenom s „flip-flop“ poklopcem.
1 ml solution for injection contains 0.6 mg pasireotide (as pasireotide diaspartate).
1 ml otopina za injekciju sadrži 0,6 mg pasireotida (u obliku pasireotiddiaspartata).
1 ml solution for injection in pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating.
1 ml otopine za injekciju u napunjenoj štrcaljki, staklo tipa I, s pričvršćenom čeličnom iglom za injiciranje i gumenim čepom obloženim politetrafluoroetilenom (PTFE-om).
1 ml solution in a pre-filled syringe (type I glass) with a tip cap (bromobutyl rubber), a plunger stopper (teflonised chlorobutyl rubber) and an injection needle (stainless steel) or an injection needle (stainless steel) with a safety shield (safety needle) or an injection needle (stainless steel) with a safety device.
1 ml otopine u napunjenoj štrcaljki (staklo tip I) sa zatvaračem vrha (bromobutil guma), čepom klipa (teflonizirana klorobutil guma) i injekcijskom iglom (nehrđajući čelik) ili injekcijskom iglom (nehrđajući čelik) sa sigurnosnim štitnikom (sigurnosna igla) ili injekcijskom iglom (nehrđajući čelik) sa sigurnosnom napravom.
1 ml solution in a type I clear glass syringe.
1 ml otopine u prozirnoj staklenoj štrcaljki (staklo tipa I).
1 mL solution in a type I glass 1 mL syringe with a fixed stainless steel needle and a needle cover containing dry natural rubber (a derivative of latex).
1 mL otopine u štrcaljki od 1 ml, izrađenoj od stakla tipa 1, s pričvršćenom iglom od nehrđajućeg čelika i pokrovom igle koji sadrži suhu prirodnu gumu (derivat lateksa).
1 mL solution in a type I glass 2 mL vial closed with a coated butyl rubber stopper.
1 mL otopine u bočici od 2 ml, izrađenoj od stakla tipa I i zatvorenoj obloženim čepom od butilne gume.
1 ml sterile solution contains 0.1-300 GBq Yttrium (90Y) on the reference date and time (corresponding to 0.005-15 micrograms of Yttrium [90Y]) (as Yttrium [90Y] chloride).
1 ml sterilne otopine sadrži 0,1-300 GBq itrija (90Y) na dan i sat umjeravanja (ekvivalent 0,005-15 mikrograma itrija [90Y]) (u obliku itrijeva [90Y] klorida).
1 ml suspension contains
1 ml suspenzije sadrži
1 ml suspension contains 100 international units insulin human (30% as soluble insulin and 70% as isophane insulin) (equivalent to 3.5 mg),
1 ml suspenzije sadrži 100 internacionalnih jedinica humanog inzulina (30% otopine inzulina i 70% izofan inzulina) (što odgovara 3,5 mg),
1 ml suspension in a vial (type I glass) with a stopper (butyl rubber) for 2 doses.
1 ml suspenzije u bočici (staklo tip I) s čepom (butil guma) za 2 doze.
1 ml suspension in type I glass pre-filled syringe, containing a plunger with a halogenobutyl end and closed with a halogenobutyl stopper.
1 ml suspenzije u tip I staklena šprica, koja sadrži klip od halogenobutila zatvorenog s halogenobutil čepom.
1 ml suspension in type I glass vial closed with a halogenobutyl rubber stopper and sealed with an aluminium cap.
1 ml suspenzije u tip I staklena bočica zatvorena sa halogenobutil gumenim čepom i zapečaćen sa aluminijskim čepom.
1 ml syringe) and injection needle (e.g.
od 1 ml) i iglu za injekcije (npr.
1 ml vial
Bočica od 1 ml
1 ml vial and 1 ml pre-filled syringe
1 ml bočice i 1 ml punjene igle
1 ml/minute.
1 ml/minuti.
1 mL/pre-filled syringe
1 ml/napunjena štrcaljka
1 mL/vial
1 ml/bočica
1 ml: Dexmedetomidine hydrochloride 0.1 mg
1 ml: deksmedetomidin hidroklorid 0,1 mg
1 month after booster
1 mjesec nakon boostera
1 month after booster
1 mjesec nakon docjepljivanja
1 MP, 1 PIP (n=58)
Različiti prsti, 1 MP, 1 PIP (n=58)
1 multidose container
EU/1/09/590/012
1 multidose pre-filled pen
1 višedozna napunjena brizgalica
1 multiple dose vial, 6 injection syringes of 1 mL, 6 injection needles and 12 cleansing swabs 1 multiple dose vial, 6 injection syringes with attached needle and needle protection device of 1 mL and 12 cleansing swabs 1 multiple dose vial, 6 injection syringes with attached needle of 1 mL and 12 cleansing swabs 2 multiple dose vials 2 multiple dose vials, 12 injection syringes of 1 mL, 12 injection needles and 24 cleansing swabs 2 multiple dose vial, 12 injection syringes with attached needle and needle protection device of 1 mL and 24 cleansing swabs 2 multiple dose vial, 12 injection syringes with attached needle of 1 mL and 24 cleansing swabs 12 multiple dose vials 12 multiple dose vials, 72 injection syringes of 1 mL, 72 injection needles and 144 cleansing swabs 12 multiple dose vial, 72 injection syringes with attached needle and needle protection device of 1 mL and 144 cleansing swabs 12 multiple dose vial, 72 injection syringes with attached needle of 1 mL and 144 cleansing swabs
1 višedozna bočica, 6 štrcaljki za injekciju od 1 ml, 6 igala za injekciju i 12 tupfera za čišćenje 1 višedozna bočica, 6 štrcaljki za injekciju s pričvršćenom iglom i uređajem za zaštitu igle od 1 ml i 12 tupfera za čišćenje 1 višedozna bočica, 6 štrcaljki za injekciju s pričvršćenom iglom od 1 ml i 12 tupfera za čišćenje 2 višedozne bočice 2 višedozne bočice, 12 štrcaljki za injekciju od 1 ml, 12 igala za injekciju i 24 tupfera za čišćenje 2 višedozne bočice, 12 štrcaljki za injekciju s pričvršćenom iglom i uređajem za zaštitu igle od 1 ml i 24 tupfera za čišćenje 2 višedozne bočice, 12 štrcaljki za injekciju s pričvršćenom iglom od 1 ml i 24 tupfera za čišćenje 12 višedoznih bočica 12 višedoznih bočica, 72 štrcaljke za injekciju od 1 ml, 72 igle za injekciju i 144 tupfera za čišćenje 12 višedoznih bočica, 72 štrcaljke za injekciju s pričvršćenom iglom i uređajem za zaštitu igle od 1 ml i 144 tupfera za čišćenje 12 višedoznih bočica, 72 štrcaljke za injekciju s pričvršćenom iglom od 1 ml i 144 tupfera za čišćenje
1 NAME OF MEDICINAL PRODUCT
1 NAZIV LIJEKA
1 NCI CTC Grade 2 constipation is defined as requiring laxatives, Grade 3 as an obstipation requiring manual evacuation or enema, Grade 4 as an obstruction or toxic megacolon.
1 Konstipacija 2. stupnja prema kriterijima NCI CTC definira se kao konstipacija koja zahtjeva primjenu laksativa, 3. stupanj označava opstipaciju koja zahtjeva ručnu evakuaciju stolice ili primjenu klizme, dok 4. stupanj označava opstrukciju ili toksični megakolon.
1 NCI CTC Grade 2 constipation is defined as requiring laxatives, Grade 3 as an obstipation requiring manual evacuation or enema, Grade 4 as an obstruction or toxic megacolon.
1 Konstipacija 2. stupnja prema kriterijima NCI CTC definira se kao konstipacija koja zahtjeva primjenu laksativa, 3. stupanj označava opstipaciju koja zahtjeva ručnu evakuaciju stolice ili primjenu klizme, dok, 4. stupanj označava opstrukciju ili toksični megakolon.
1 NCI CTCAE v 4.0 = National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
1 NCI CTCAE v 4.0 = Zajednički kriteriji terminologije za nuspojave Nacionalnog instituta za rak verzija 4.0
1 NCI CTCAE v 4.0 = National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
1 NCI CTCAE v 4.0= Zajednički kriteriji terminologije za nuspojave Nacionalnog instituta za rak verzija 4.0
1 needle for preparation
1 igla za pripremu
1 needle for preparation
1 iglu za pripremu
1 Neutropenic colitis, including fatal neutropenic colitis, has been reported to occur as a complication of topotecan-induced neutropenia (see section 4.4)
1 Kao komplikacija neutropenije izazvane topotekanom prijavljen je neutropenijski kolitis, ponekad sa smrtnim ishodom (vidjeti dio 4.4)
1 Neutropenic colitis, including fatal neutropenic colitis, has been reported to occur as a complication of topotecan-induced neutropenia (see section 4.4)
1 Kao komplikacija neutropenije izazvane topotekanom prijavljen je neutropenijski kolitis, ponekad sa smrtnim ishodom (vidjeti dio 4.4).
1 not attenuated
1 neatenuirano
1 Not used to calculate physician rating of severity at baseline percentage – actual denominator of N=247 used.
1 Nije korišteno za izračunavanje postotka liječnički ocjenjene početne težine – stvarni nazivnik koji se koristio je N=247.
1 Number of patients with available data
1 Broj bolesnika s dostupnim podacima
1 Observed during use in lumbar interbody fusion
1 Uočeno tijekom uporabe u interkorporalnoj fuziji lumbalne kralježnice.
1 OJ No L 290 of 05.12.95
1 OJ No L 290 od 05.12.95
1 Once-daily regimen + insulin aspart to cover mealtime insulin requirements  metformin  pioglitazone 2 Once-daily regimen  metformin SU/glinide  pioglitazone
1 Primjena jednom dnevno + aspart inzulin za pokrivanje potreba za inzulinom u vrijeme obroka  metformin  pioglitazon 2 Primjena jednom dnevno  metformin SU/glinid  pioglitazon
1 or 10 pre- filled syringes with or without needle
1 ili 10 napunjenih štrcaljki s iglom ili bez igle.
1 or more NNRTI resistance-associated mutations (RAMs) at screening or from prior genotypic analysis (i.e., archived resistance)
1 ili više mutacija povezanih s NNRTI rezistencijom (RAM, eng. resistance-associated mutations) na probiru ili u prethodnoj genotipizaciji (tj. (arhivirana rezistencija)
1 Organ region of interest
1 Područje organa od interesa
1 Other efavirenz resistance mutations included A98G (n=1), K103E (n=1), V179D (n=1), and M230L (n=1).
1 Druge mutacije za rezistenciju na efavirenz uključivale su A98G (n=1), K103E (n=1), V179D (n=1) i M230L (n=1).
1 p-value for PFS/OS based on stratified log-rank test
1 p-vrijednost za PFS/OS temeljena na stratificiranom log-rank testu
1 p-value for PFS/OS based on stratified log-rank test; p-value for Objective Response Rate based on logistic regression
1 p-vrijednost za PFS/OS temeljena na stratificiranom log-rank testu; p-vrijednost za stopu objektivnog odgovora temeljena na logističkoj regresiji
1 p-values < 0.0001
1p-vrijednosti  0,0001